Skip to main content
Caplight Logo









RIGImmune Inc.

RIGImmune Inc.

Private
Farmington, ConnecticutHealthcare & Life Scienceshttps://rigimmune.com/

Last Round

Series A

Apr 1, 2024

Est. Valuation

$18.25M

Total Funding Raised

$15M

Company Overview

RIGImmune Inc. is a biopharmaceutical company developing a new class of RNA immunotherapeutics that selectively activate the innate immune sensor RIG-I to treat diseases caused by RNA viruses and to induce antitumor immune responses.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA therapeuticsbiotechnologyRIG-I agonistdrug delivery platformmRNA therapeuticsbiopharmarespiratory disease treatmentnano-emulsion deliveryoncology therapeuticsinnate immune pathwaypreclinical drug developmentinhaled drug deliverydrug discoverynon-lipid nanoparticlebiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RIGImmune Inc. Comparables

Compare RIGImmune Inc. with similar companies based on industry and business-model similarity.

RIGImmune Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Merck & Co., Inc.
77%
Xanadu Bio
77%
NorthLinks Bio
76%

RIGImmune Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 1, 2024
GrantDec 7, 2022
VC RoundDec 7, 2022
VC RoundSep 15, 2022
SeedDec 10, 2021

Key People

Founding team and executive leadership

Jag Shur

Chief Technology Officer Head of Drug Delivery

Executive Team

RIGImmune Inc. Investors

Notable investors and investment history

RIGImmune Inc. investors
InvestorRounds
Rivermount VenturesVC Round
Bill & Melinda Gates FoundationVC Round, Grant
Yale VenturesSeed
F-Prime CapitalVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 3, 2026

    Monthly visitors increased 219% MoM.

  • Apr 1, 2024

    Completed a Series A funding round.

RIGImmune Inc. Filings

Explore SEC and related filing metadata, where available.

RIGImmune Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about RIGImmune Inc.'s valuation, stock price, and market status.

Is RIGImmune Inc. a public or private company?

RIGImmune Inc. is a private company.

What is the current stock price of RIGImmune Inc.?

RIGImmune Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is RIGImmune Inc. worth (valuation)?

Valuation information for RIGImmune Inc. is not publicly available.

Can I buy RIGImmune Inc. stock?

RIGImmune Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was RIGImmune Inc.'s last funding round?

Funding round information for RIGImmune Inc. is not publicly available.

Who are the main investors in RIGImmune Inc.?

Investor information for RIGImmune Inc. is not publicly disclosed.

Will RIGImmune Inc. IPO soon?

No public IPO plans have been announced for RIGImmune Inc..

How can I track RIGImmune Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor RIGImmune Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersFarmington, Connecticut
Employee Range9
Year Founded2020
Last FundingApr 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?